ZRO Biosenta Inc

University of Calgary research on Biosenta filler particles yields very encouraging results for the construction industry in the fight against bacteria

University of Calgary research on Biosenta filler particles yields very encouraging results for the construction industry in the fight against bacteria

CALGARY, Alberta, May 25, 2022 (GLOBE NEWSWIRE) -- Biosenta Inc. (the “Company” or “Biosenta”) (CSE: ZRO) is developing environmentally friendly biocidal particles that are successfully tested against infectious bacteria growing on common surfaces. The particles are developed in collaboration with Dr. Maen Husein’s laboratory, University of Calgary, and tested in Dr. Ian Lewis’s laboratory, University of Calgary. Preliminary results showed that inclusion of the particles into cement provides effective biocidal attributes.

“It is critical to tune the morphology of the particles for optimum performance,” said Dr. Husein.

“We are thrilled about our collaboration with Biosenta and are excited about the new data that is emerging from our collaboration,” said Dr. Lewis.

“Mass production of the particles is feasible,” said Noora, a PhD student working on developing the particles.

“The biocidal efficacy of the particles will be tested against Corona virus, including COVID 19, in the near future,” said Dr. Ashani, a postdoctoral fellow testing the biocidal efficacy of the particles.”

“The findings are very encouraging and would have a profound impact in the construction industry because of the aniti-microbial properties of the particles. We are pleased to see the outcome of the research by University of Calgary, which proves the science behind Biosenta that has been years in the making,” said Am Gill, CEO of Biosenta.

Further research will be conducted this summer on multiple construction surfaces such drywall, paint, plastic, glass carpet etc. Research funds from Biosenta are matched by Mitacs Accelerate funding that builds partnerships between academia, industry, and the world. 

About Biosenta Inc  

Biosenta Inc. develops and manufactures a range of chemical compounds for household and industrial applications using advanced encapsulated nanotechnology. 

Disclaimer

The CSE has in no way passed upon the contents of this news release and further, has neither approved nor disapproved of the contents of this news release. Neither the CSE nor its Regulation Services Provider (as such term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This press release contains forward-looking information within the meaning of applicable securities laws (“forward-looking statements”), including forward-looking statements relating the completion of the Transaction. Such forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements to differ materially from the anticipated results, performance or achievements or developments expressed or implied by such forward-looking statements. If any such risks actually occur, they could impact the potential for discussion, agreement or completion of the Transaction and/or materially adversely affect the Company’s business, financial condition or results of operations. In that case, the trading price of the Company’s common shares could decline, perhaps materially. Readers are cautioned not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Forward-looking statements are provided for the purposes of providing information about management’s current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in the Company’s expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.

For Enquiries, please contact 

Am Gill, President and CEO 

Ph. (403) 830-7667 

 



EN
25/05/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Biosenta Inc

 PRESS RELEASE

Biosenta Announces Breakthrough Discovery in Anti-Microbial Efficacy o...

Biosenta Announces Breakthrough Discovery in Anti-Microbial Efficacy of Tri-Filler™ in Collaboration with Dr. Ian Lewis and Dr. Maen Husein's Labs TORONTO and CALGARY, Alberta, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Biosenta Inc. (“Biosenta” or the “Company”) (CSE: ZRO) is thrilled to announce a pivotal discovery led by Dr. Mehdi Mohammadi Ashani, a Postdoctoral Researcher under the mentorship of Dr. Ian Lewis and Dr. Maen Husein at the University of Calgary. Utilizing the advanced capabilities of the Alberta Centre for Advanced Diagnostics (ACAD), this research has revealed that Tri-Filler™,...

 PRESS RELEASE

Biosenta builds on partnership with AMPAK to test and commercialize Tr...

Biosenta builds on partnership with AMPAK to test and commercialize Tri-Filler™ CALGARY, Alberta, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Biosenta Inc. (“Biosenta” or the “Company”) listed on the CSE (CSE: ZRO) is pleased to announce the next level of partnership with AMPAK Inc. and the University of Calgary. The new Agreement will see Tri-Filler™ being tested in plastics at AMPAK Inc. facilities with an eye to commercialization. Further to the announcement of the partnership on September 24th, 2020, AMPAK Inc. has signed a new agreement with Biosenta and the University of Calgary that will g...

 PRESS RELEASE

Biosenta announces further advances in research and development of Tri...

Biosenta announces further advances in research and development of Tri-Filler™ TORONTO and CALGARY, Alberta, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Biosenta Inc. (“Biosenta” or the “Company”) (CSE: ZRO) is pleased to announce further advances in research and development of the Tri-Filler™ particle composed of Ca(OH)2 (calcium hydroxide) core with a CaCO3 (calcium carbonate) encapsulation. Ongoing development of new methods of production of Tri-Filler™ by Dr. Maen Husein of the Department of Chemical Engineering at the University of Calgary and his team have reduced aggregation and resulted in ...

 PRESS RELEASE

Biosenta Inc. ceases negotiations with Voran Group Ventures Ltd.

Biosenta Inc. ceases negotiations with Voran Group Ventures Ltd. CALGARY, Alberta, May 31, 2023 (GLOBE NEWSWIRE) -- Biosenta Inc. ( “Biosenta”) (CSE: ZRO) announces that, further to its news release dated October 12, 2022, it has ceased negotiations with Voran Group Ventures Ltd. in respect of the previously announced Memorandum of Understanding dated October 5, 2022, for the commercialization of Biosenta’s Tri-Filler® antimicrobial products in Canadian markets and worldwide. About Biosenta Inc. Biosenta is a Canadian-based company that develops and manufactures a range of safe and envi...

 PRESS RELEASE

Biosenta Inc. Enters into an MOU with Voran Group Ventures Ltd. to col...

Biosenta Inc. Enters into an MOU with Voran Group Ventures Ltd. to collaborate on the commercialization of Biosenta’s Tri-Filler® Products CALGARY, Alberta, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Biosenta Inc. (the “Company” or “Biosenta”) (CSE: ZRO) has signed a milestone Memorandum of Understanding dated October 5, 2022, with VORAN GROUP VENTURES Ltd. (“Voran”) which will lead the way for the commercialization of Biosenta’s Tri-Filler® antimicrobial products in Canadian markets and worldwide. The patented new material science Tri-Filler® products could set the new standard in antimicrobial ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch